Melasma and Lasers: Why More Power Usually Makes It Worse

Walk into almost any laser consultation in Beverly Hills with stubborn brown patches across the cheeks or forehead, and there is a good chance the conversation will turn to melasma. It is one of the most common pigment complaints in Southern California, driven by year-round ultraviolet exposure, hormones, and genetics. It is also, according to a broad consensus in dermatology literature, one of the easiest conditions to make worse with the wrong laser. The persistent myth is simple: if pigment is the problem, blast the pigment. The clinical reality is more complicated, and understanding why can save patients months of frustration and thousands of dollars.

The myth: melasma is just surface pigment, so a strong laser can remove it. This framing treats melasma like a tattoo or a sun spot, a fixed deposit of color that a laser can shatter and the body can clear. Melasma does not behave that way. It is better understood as a chronic, relapsing condition in which melanocytes, the pigment-producing cells, are abnormally reactive. They overproduce melanin in response to ultraviolet light, visible light, heat, and inflammation. The pigment a patient sees in the mirror is the output of the disease, not the disease itself. For an independent overview, see Melasma and pigmentation: diagnosis and treatment.

Why heat backfires. Most pigment lasers work through selective photothermolysis: a wavelength absorbed by melanin delivers energy fast enough to damage the pigment target while sparing surrounding tissue. In a benign sun spot, that works well because the melanocytes there are not hyperreactive. In melasma, the same thermal insult acts as a trigger. Heat and inflammation stimulate signaling pathways that tell melanocytes to produce more melanin, a response called post-inflammatory hyperpigmentation. The result many patients experience is a brief lightening at two to four weeks, followed by a rebound that is darker and often more diffuse than the original patch. Higher energy settings raise the odds of this rebound rather than lowering them. There is also a second failure mode: aggressive treatment can destroy melanocytes outright in scattered spots, leaving confetti-like white marks called guttate hypopigmentation, which are frequently permanent.

What the evidence supports instead. When lasers are used for melasma at all, the trend in published studies is toward low-fluence, large-spot approaches, sometimes called laser toning, typically with a 1064 nanometer Q-switched or picosecond device. The goal is subthreshold injury: enough energy to fragment existing melanin granules inside cells so the body can clear them, but not enough heat to inflame the melanocyte and provoke new production. Even this gentler strategy has caveats. Studies report meaningful recurrence within months if treatments stop, and repeated frequent sessions carry their own hypopigmentation risk. Non-thermal options such as low-density fractional lasers and certain radiofrequency microneedling protocols appear in the literature as adjuncts, again with modest, maintenance-dependent results.

Lasers are rarely the first move. Most evidence-based melasma plans in 2024 era guidelines start with topicals and photoprotection, not devices. Tinted mineral sunscreen matters more than most patients expect, because iron oxides block visible light, and visible light alone can darken melasma in medium and deeper skin tones. Prescription regimens built around hydroquinone or triple-combination creams, along with agents like azelaic acid, tranexamic acid, and cysteamine, form the backbone of treatment. Oral tranexamic acid, prescribed with appropriate screening, has some of the strongest recent data for resistant cases. In this framework, a laser is a possible third-line tool for pigment that persists after the biology has been calmed down, not an opening bid.

Skin tone raises the stakes. Beverly Hills practices see a wide range of Fitzpatrick skin types, and melasma disproportionately affects types III through V, the same skin types most prone to post-inflammatory hyperpigmentation. The more baseline melanin in the epidermis, the more competing target there is for the laser, and the narrower the margin between a therapeutic dose and a harmful one. This is why experienced providers often insist on a test spot, several weeks of pre-treatment with pigment-suppressing topicals, and conservative settings, even when a patient is eager for faster results.

Questions worth asking at a consultation. How do you confirm this is melasma rather than another pigment condition, and do you use a Wood's lamp or dermoscopy? What happens if I rebound, and what is your protocol for managing it? Why this device and this fluence for my skin type? What is the maintenance plan after the series ends? A provider who answers these fluently, and who talks as much about sunscreen and topicals as about the machine, is generally operating within the evidence.

The bottom line: melasma is a management condition, closer to a chronic disease than a removable mark. Lasers can play a careful supporting role, but the strongest device in the room is not the right tool, and in this one corner of aesthetic medicine, restraint is the most advanced technique available.

Related reading: Can Laser Make Melasma Worse? A Myth Check.